ENANTA PHARMACEUTICALS, INC Accrued Liabilities, Current
ENANTA PHARMACEUTICALS, INC (ENTA) had Accrued Liabilities, Current of $10.18 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-12
- 2026-06-30: Accrued Liabilities, Current $10.18M.
- 2026-03-31: Accrued Liabilities, Current $6.86M.
- 2025-12-31: Accrued Liabilities, Current $7.58M.
- 2025-09-30: Accrued Liabilities, Current $12.75M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $10.18M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $6.86M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $7.58M 10-Q · filed 2026-02-11 |
| 2025-09-30 | $12.75M 10-Q · filed 2026-08-12 |
| 2025-06-30 | $10.85M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $8.31M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $10.57M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $13.55M 10-K · filed 2025-11-19 |
| 2024-06-30 | $12.83M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $10.63M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $11.60M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $18.34M 10-K · filed 2024-11-27 |
| 2023-06-30 | $18.20M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $15.48M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $15.16M 10-Q · filed 2023-02-08 |
| 2022-09-30 | $20.94M 10-K · filed 2023-11-22 |
| 2022-06-30 | $19.19M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $21.74M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $26.58M 10-Q · filed 2022-02-10 |
| 2021-09-30 | $22.43M 10-K · filed 2022-11-23 |
| 2021-06-30 | $17.70M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $15.74M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $11.54M 10-Q · filed 2021-02-09 |
| 2020-09-30 | $14.16M 10-K · filed 2021-11-24 |
| 2020-06-30 | $13.58M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $9.81M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $9.41M 10-Q · filed 2020-02-10 |
| 2019-09-30 | $15.92M 10-K · filed 2020-11-25 |
| 2019-06-30 | $14.00M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $11.61M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $11.15M 10-Q · filed 2019-02-08 |
| 2018-09-30 | $9.89M 10-K · filed 2019-11-27 |
| 2018-06-30 | $9.13M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $7.04M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $5.70M 10-Q · filed 2018-02-09 |
| 2017-09-30 | $7.97M 10-K · filed 2018-11-29 |
| 2017-06-30 | $5.63M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $5.10M 10-Q · filed 2017-05-10 |
| 2016-12-31 | $4.48M 10-Q · filed 2017-02-09 |
| 2016-09-30 | $4.51M 10-K · filed 2017-12-11 |
| 2016-06-30 | $4.58M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $2.63M 10-Q · filed 2016-05-10 |
| 2015-12-31 | $3.17M 10-Q · filed 2016-02-09 |
| 2015-09-30 | $3.96M 10-K · filed 2016-12-09 |
| 2015-06-30 | $3.47M 10-Q · filed 2015-08-10 |
| 2015-03-31 | $2.91M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $2.40M 10-Q · filed 2015-02-06 |
| 2014-09-30 | $2.87M 10-K · filed 2015-12-11 |
| 2014-06-30 | $2.98M 10-Q · filed 2014-08-12 |
| 2014-03-31 | $2.33M 10-Q · filed 2014-05-12 |
| 2013-12-31 | $1.72M 10-Q · filed 2014-02-13 |
| 2013-09-30 | $3.04M 10-K · filed 2014-12-11 |
| 2013-06-30 | $2.02M 10-Q · filed 2013-08-12 |
| 2013-03-31 | $2.46M 10-Q · filed 2013-05-15 |
| 2012-09-30 | $3.87M 10-K · filed 2013-12-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |